FEB 09, 2017 09:00 AM PST
Improved decision making in the drug discovery process using an innovative approach to modelling chronic liver disease
Presented at the Laboratory Animal Sciences 2017 Virtual Event
2 1 57

Speakers:
  • Director & Head of Future Therapeutics & Technologies, Abbvie
    Biography
      Steve is an experienced professional in the early stages of drug discovery and development -from target identification, through project initiation up to proof of concept. This has been gained at Pfizer, AstraZeneca and Abbott/AbbVie. Steve has broad-based scientific expertise, primarily in the neuroscience area and more recently in chronic liver disease and more generally in immunology and oncology. Throughout his career Steve has managed both large and small groups of scientists and established a number of successful external collaborations with both academics and small companies. Currently Steve has two major roles - Firstly, leading the Discovery effort focused on liver disease at AbbVie, aimed at identifying treatments for NASH/NAFLD and also autoimmune diseases of the liver. Secondly, Steve head Future Therapeutics & Technologies - a team tasked with the identification and 'internalisation' of atypical therapeutic modalities.

    Abstract:

    DATE: February 9, 2017
    TIME: 9:00am PT, 12:00pm ET

    Traditional models of liver fibrosis in rodents involve many weeks of induction, with frequent injections of a pro-fibrotic agent. The most commonly used end-point in these studies is immuno-histochemical analysis of markers of fibrosis in the liver. This whole process is time-consuming, very labor-intensive in terms of animal handling, processing of the tissues and produces only a semi-quantitative measure of fibrosis. In addition, if pharmacological agents are to be explored, this means more ‘hands-on’ work for the experimentalist due to the likelihood of the need for daily dosing and adds substantially to the cost of the study because of the amounts of compound required. We have modelled the inflammatory component which drives liver fibrosis, by using the concanavalin A (conA) challenge to evoke an acute liver inflammation and the Vium ‘Digital Vivarium’ as a way of monitoring mouse behavior in response to the challenge. Acute liver inflammation evokes measurable changes in mouse behavior over the course of 24hrs and we believe these behavioral measures will be useful in testing the efficacy of pharmacological agents which suppress the inflammation.  By focusing on the inflammatory drivers of the pathology we dramatically reduce the duration of the studies, obtain a quantitative measure of the effect of the conA whilst minimizing handler intervention and reduce compound demand. Moreover, we believe the value of efficient in vivo testing of hypotheses enables us to embrace ‘systems biology’ in a way that is entirely compatible with aspects of the ‘3Rs’. Using a behavioral assessment of inflammation enables us to make rapid decisions on mechanisms and targets of interest. This reduces costs and time but maybe more importantly, promotes improved iterative decision-making regarding targets and compounds.


    Show Resources
    Loading Comments...